公开(公告)号：US20250066793A1

公开(公告)日：2025-02-27

申请号：US18724758

申请日：2022-12-28

Applicant: Development Center for Biotechnology

Inventor： Ying-Shuan LAILEE ,  Chia-Wei LIU ,  Chi-Tang WANG ,  Pei-Yi TSAI ,  Chung-Hsiun WU ,  King LAM ,  Wei-Ting SUN ,  Kai-Chien YANG ,  Hung-Jyun HUANG

IPC: C12N15/113 ,  A61P11/00

Abstract: Disclosed herein are novel single-stranded anti-sense oligonucleotides (ASOs) capable of reducing the transcription of thioredoxin domain containing protein 5 (TXNDC5) mRNA. Also disclosed is use of the single-stranded ASOs as disclosed herein for manufacturing medicaments suitable for treating a disease associated with upregulation of TXNDC5. Accordingly, a pharmaceutical composition comprising the disclosed ASO molecules is provided; as well as a method of treating a subject suffering from TXNDC5-mediated disease via administering to the subject the disclosed single-stranded ASO molecules.

公开(公告)号：US12187806B2

公开(公告)日：2025-01-07

申请号：US17686666

申请日：2022-03-04

Applicant: Development Center for Biotechnology

Inventor： Chun-Chung Lee ,  Yu-Hsun Lo ,  Chu-Bin Liao ,  Chen-Jei Hong ,  Sih-Yu Chen ,  Yen-Yu Wu ,  Szu-Liang Lai ,  Chih-Yung Hu ,  Wen-Bin Ke ,  Ya-Ting Juan ,  Kao-Jean Huang

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61K39/00

Abstract: The present invention relates to a novel antibody, an antigen-binding fragment thereof and the uses of the antibody and fragment, wherein the antibody and the fragment comprise specific complementarity-determining regions (CDRs) and/or specifically bind to human CD73 at specific epitopes.

公开(公告)号：US20220289759A1

公开(公告)日：2022-09-15

申请号：US17636116

申请日：2020-08-22

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shao-Zheng PENG ,  Chu-Bin LIAO ,  Hung-Jyun HUANG ,  Yuan-Ting CHO ,  Yi-Mei CHANG ,  Yu-Chih PAN

IPC: C07D495/04 ,  C07D519/00 ,  A61P35/00

Abstract: A compound, which can act as inhibitors of protein kinases, especially Class III RTKs such as FLT3, PDGFRα, c-KIT and/or CSF-1R kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a binder of a Proteolysis-Targeting Chimera (PROTAC) thereof. The compound can be used in the treatments of diseases or conditions mediated by FLT3, PDGFR, c-KIT, and/or CSF-1R kinases, or mediated by a mutant kinase of FLT3, PDGFR, c-KIT, and/or CSF-1R kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

公开(公告)号：US20220064310A1

公开(公告)日：2022-03-03

申请号：US17413496

申请日：2019-12-13

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Chen-Hsuan HO ,  Chu-Bin LIAO ,  Yu-Kai CHEN ,  Chen-Wei HUANG ,  Tze-Ping YANG ,  Szu-Liang LAI

IPC: C07K16/28 ,  A61P35/00

Abstract: An antibody, or an antigen-binding fragment thereof, that binds specifically to human CSF-1R includes a heavy chain variable domain that contains a HCDR1 region having the sequence of SEQ ID NO: 4, a HCDR2 region having the sequence of SEQ ID NO: 5, and a HCDR3 region having the sequence of SEQ ID NO: 6; and a light chain variable domain that contains a LCDR1 region having the sequence of SEQ ID NO: 7, a LCDR2 region having the sequence of SEQ ID NO: 8, and a LCDR3 region having the sequence of SEQ ID NO: 9. The heavy chain variable domain comprises the sequence of SEQ ID NO: 2, and wherein the light chain variable domain comprises the sequence of SEQ ID NO: 3.

公开(公告)号：US20210388046A1

公开(公告)日：2021-12-16

申请号：US17417112

申请日：2019-12-23

Applicant: Development Center for Biotechnology

Inventor： Chao-Yi TENG ,  Ying-Ju CHEN

IPC: C07K14/47 ,  C07K14/705 ,  C12N9/16 ,  C07K16/00

Abstract: A chimeric signal peptide for protein expression includes an N-region, a hydrophobic region, and a C-region, wherein the N-region and the C-region are from a same signal peptide of a first protein and the hydrophobic region is from a signal peptide of a second protein, wherein the first protein is different from the second protein. The first and second protein are independently selected from the group consisting of BM40, IL2, HA, Insulin, CD33, IFNA2, IgGK leader, AZU, and SEAP.

公开(公告)号：US20210052719A1

公开(公告)日：2021-02-25

申请号：US16959117

申请日：2017-12-29

Applicant: Development Center for Biotechnology

Inventor： Jia-Ming CHANG ,  Wan-Jyun WEI

IPC: A61K39/145 ,  C07K14/005

Abstract: An antigenic short peptide includes 11 to 15 amino-acid residues and has an ability to induce antibody against influenza virus. The sequence of the antigenic peptide is selected from hemagglutinin (HA). The antigenic peptide includes the sequence of JJ (SEQ ID NO:2), JJ-1 (SEQ ID NO:3), JJ-2 (SEQ ID NO:4), JJ-3 (SEQ ID NO:5) or JJ-4 SEQ ID NO:6). A method for inducing a broad-spectrum immunity against influenza viruses includes administering a vaccine to a subject, wherein the vaccine comprises one of the above antigenic peptide.

公开(公告)号：US10793542B2

公开(公告)日：2020-10-06

申请号：US16462589

申请日：2017-11-22

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Mann-Yan Kuo ,  Ying-Shuan Lee ,  Yann-Yu Lu ,  Chia-Wei Liu ,  Seline Hsieh ,  Ju-Ying Yang

IPC: C07D213/74 ,  C07D239/47 ,  C07D239/48 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  A61P35/00 ,  C07D239/38 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  A61K45/06

Abstract: The present invention provides a compound of formula (1): wherein X, Y, Z1, Z2, R1, R2, A, B, p and q are as disclosed in the specification. A pharmaceutical composition and a method for modulating the Hedgehog pathway are also provided. The present invention rurthe r provides a process for preparing the compound.

公开(公告)号：US10781266B2

公开(公告)日：2020-09-22

申请号：US15924878

申请日：2018-03-19

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY ,  NATIONAL HEALTH RESEARCH INSTITUTES

Inventor： Shih-Chong Tsai ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Jiann-Shiun Lai ,  Chia-Cheng Wu ,  Po-Yin Lin ,  Ya-Wei Tsai ,  Chao-Yang Huang ,  Ying-Yung Lok ,  Chung-Hsiun Wu ,  Hsien-Yu Tsai ,  Neng-Yao Shih ,  Ko-Jiunn Liu ,  Li-Tzong Chen

IPC: A61K39/00 ,  C07K16/40 ,  A61P35/00 ,  G01N33/574

Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.

公开(公告)号：US10752688B2

公开(公告)日：2020-08-25

申请号：US15859506

申请日：2017-12-30

Applicant: Development Center for Biotechnology

Inventor： Yu-Chen Yang ,  Li-Yu Chen ,  Chia-Hua Li ,  Pei-Han Tai ,  Hong-Kai Chen ,  Ying-Yung Lok ,  Chih-Yung Hu ,  Chien-Tsun Kuan ,  Chung-Hsiun Wu

IPC: C07K16/00 ,  C07K16/28 ,  A61P35/00 ,  G01N33/574 ,  A61K39/00

Abstract: An anti-human T-cell immunoglobulin domain and mucin domain 3 (TIM-3) antibody, can bind the peptides, comprising the amino-acid sequence RKGDVSL (SEQ ID NO: 9) and/or EKFNLKL (SEQ ID NO: 10) of human TIM-3 protein. The antibody can regulate immune cell activity. The antibody or binding fragment thereof is useful in diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface TIM-3 such as lung, liver, esophageal cancer and solid tumors.

公开(公告)号：US20170369525A1

公开(公告)日：2017-12-28

申请号：US15541020

申请日：2015-12-31

Applicant: Development Center for Biotechnology ,  DCB-USA LLC

Inventor： Chao-Pin Lee ,  Cheng-Chou Yu ,  Chi-Huey Wong ,  Chuan-Lung Hsu ,  Chun-Chung Lee ,  Shih-Hsien Chuang ,  Ta-Tung Yuan ,  Yi-Jen Chen ,  Yu-Chin Nieh

IPC: C07K1/107 ,  C07K1/08 ,  A61K39/395 ,  C07K16/18 ,  A61K47/68

CPC classification number: C07K1/1077 ,  A61K39/395 ,  A61K47/6803 ,  A61K47/6855 ,  A61K47/6889 ,  A61K49/0043 ,  A61K49/0058 ,  C07K1/08 ,  C07K16/18

Abstract: A method for specific linkage to a glycoprotein includes obtaining a glycoprotein having a monoglycan or diglycan attached thereto; producing a reactive functional group on a sugar unit on the glycoprotein; and coupling a linker or a payload to the reactive functional group on the glycoprotein.